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HUMAN INTRAOCULAR PENETRATION PHARMACOKINETICS OF 
MOXIFLOXACIN 0.5% VIA TOPICAL AND COLLAGEN SHIELD ROUTES 
OF ADMINISTRATION 
BY Seenu M. Hariprasad MD,* William F. Mieler MD, Gaurav K. Shah MD, Kevin J. Blinder MD, Rajendra S. Apte MD,
Nancy M. Holekamp MD, Matthew A. Thomas MD, Jingduan Chi PhD, AND Randall A. Prince PharmD
ABSTRACT
Purpose: To determine penetration of moxifloxacin 0.5% into human aqueous and vitreous via topical and collagen shield
routes of administration.
Methods: Moxifloxacin 0.5% was administered prior to vitrectomy surgery through one of three routes: topical drops
every 2 hours for 3 days, versus topical drops every 6 hours for 3 days, versus delivery using a 24-hour dissolvable cross-
linked corneal collagen shield. Aqueous and vitreous moxifloxacin concentrations were assayed using high-performance
liquid chromatography
Results: Mean moxifloxacin concentrations in the every-2-hour group for aqueous (n = 9) and vitreous (n = 10) were 
2.28 ± 1.23 µg/mL and 0.11 ± 0.05 µg/mL, respectively. Mean moxifloxacin concentrations in the every-6-hour group for
aqueous (n = 10) and vitreous (n = 9) were 0.88 ± 0.88 µg/mL and 0.06 ± 0.06 µg/mL, respectively. Levels of minimum
inhibitory concentration at which 90% of isolates are inhibited (MIC90) were far exceeded in the aqueous for a wide spec-
trum of pathogens that most commonly cause postoperative endophthalmitis. Moxifloxacin concentration in the vitreous
did not exceed the MIC90 for several key organisms. Delivery of moxifloxacin via a collagen shield revealed a mean aque-
ous concentration of 0.30 ± 0.17 µg/mL 4 hours after placement (n = 5). Vitreous levels at 4 hours, as well as aqueous
and vitreous levels at 24 hours, were negligible using this route of administration.
Conclusions: The findings of this investigation reveal that topically administered moxifloxacin 0.5% can achieve relatively
high aqueous concentrations. Although aqueous moxifloxacin levels achieved through the use of a collagen shield deliv-
ery device are lower, there are several advantages to this route of delivery that make it appealing in the immediate post-
operative period. Future studies will be needed to precisely define the role of fourth-generation fluoroquinolones and
presoaked collagen shields in the prophylaxis or management of intraocular infections.
Trans Am Ophthalmol Soc 2004;102:149-157
INTRODUCTION
Bacterial endophthalmitis is one of the most serious
complications after intraocular surgery. The microbiologic
spectrum of infecting organisms in postoperative endoph-
thalmitis was investigated in the Endophthalmitis
Vitrectomy Study. This study represents the largest
number of postoperative endophthalmitis cases from
which bacteriologic data were prospectively obtained. The
vast majority (94.2%) of confirmed growth isolates were
gram-positive pathogens, most commonly Staphylococcus
epidermidis and Staphylococcus aureus.  Gram-negative
pathogens, the most common being Proteus mirabilis,
accounted for only 5.9% of confirmed growth isolates.1
The spectrum of infecting organisms in post-traumatic
endophthalmitis differs from those of postoperative
endophthalmitis, with Bacillus species playing a more
prominent role.2
Numerous strategies have been described to try to
decrease the incidence of postoperative endophthalmitis.3
Unfortunately, it is difficult to demonstrate superiority of
one prophylactic strategy over another owing to the low
occurrence rate of postoperative infection. The fluoro-
quinolones have been commonly used for prophylaxis
during the perioperative period, typically through the
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topical route of administration. The choice of antibiotic
can be difficult because there are many different aspects
by which the efficacy of an antibiotic is determined. One
of these aspects is bioavailability. The bioavailability of an
antibiotic determines its ability to penetrate into the
tissues of concern and reach bacteria. In order to be
bioavailable, a topical ophthalmic antibiotic must have a
high rate of penetration and good solubility. The purpose
of this investigation is to determine the penetration phar-
macokinetics of moxifloxacin 0.5% ophthalmic solution
into the human aqueous and vitreous via topical and colla-
gen shield routes of administration.
Moxifloxacin 0.5% (Vigamox; Alcon Laboratories, Inc,
Fort Worth, Texas) and gatifloxacin 0.3% (Zymar; Allergan,
Inc, Irvine, California) are two newly released fourth-gener-
ation fluoroquinolones. They have a spectrum of activity
encompassing gram-positive and gram-negative bacteria,
including S epidermidis, S aureus, S pneumoniae, 
S pyogenes, H influenzae, E coli, Bacillus cereus, N gonor-
rhoeae, and P mirabilis. Additionally, the fourth-generation
fluoroquinolones have good activity against atypical
pathogens such as Mycoplasma, Legionella, and Chlamydia
species, as well as the anaerobic organism P acnes.4,5 New-
generation fluoroquinolones, such as moxifloxacin, gati-
floxacin, grepafloxacin, and trovafloxacin, represent
advances in the evolution of this antibiotic class. The more
favorable pharmacokinetic properties of the previously
mentioned agents are due to alterations of the original fluo-
roquinolone moiety. For example, moxifloxacin and gati-
floxacin possess an 8-methoxy side-chain (Figure 1), which
may be responsible for their enhanced activity against gram-
positive organisms, atypical pathogens, and anaerobes while
retaining potencies and broad-spectrum coverage against
gram-negative organisms comparable to older-generation
fluoroquinolones. Each of the fourth-generation fluoro-
quinolones has its own subtle strengths by in vitro testing;6,7
however, further studies will reveal if these in vitro differ-
ences are clinically relevant.
We chose to study the penetration pharmacokinetics
of topically applied moxifloxacin 0.5% ophthalmic solu-
tion into the human aqueous and vitreous for two reasons.
First, older-generation fluoroquinolones, such as ofloxacin
0.3%, ciprofloxacin 0.3%, and levofloxacin 0.5%, have
been shown to achieve effective levels in the aqueous, but
not the vitreous, after topical administration in the nonin-
flamed eye.8-10 Second, the MIC90 values of moxifloxacin
against the pathogens most commonly responsible for
postoperative, post-traumatic, and bleb-associated
endophthalmitis were generally lower than those of the
other fluoroquinolone antibiotics we surveyed (Table 1). 
The corneal collagen shield was originally developed as
a bandage lens for the treatment of corneal epithelial
damage. Prior investigations have demonstrated that the
collagen shield may be well suited for drug delivery in the
perioperative setting and has several advantages over topical
and subconjunctival routes of antibiotic administration.11-13
For these reasons, we chose to determine the intraocular
penetration of moxifloxacin 0.5% using a 24-hour dissolv-
able cross-linked corneal collagen shield device.
METHODS
The study was carried out with the approval of the
Washington University School of Medicine Institutional
Review Board. Thirty adult patients, age range 55 to 86
years (68.2 ± 7.9 years), undergoing elective pars plana
vitrectomy surgery between September 2003 and
February 2004 at the Barnes Retina Institute were
included in the study. Exclusion criteria included the
following: known sensitivity to fluoroquinolones, renal
disease (creatinine level >1.8 mg/dL), use of any other
antibiotic(s) in the preceding 3 weeks, pregnancy or
currently breast-feeding, current use of a class IA or III
antiarrhythmic agent, previously vitrectomized eyes, fresh
vitreous hemorrhage as indication for vitrectomy (less
than 1 month old), or active endophthalmitis.
After informed consent was obtained, the first 20
patients were asked to self-administer topical moxifloxacin
0.5% ophthalmic solution for 3 days prior to surgery in the
eye scheduled for operation. The first 10 patients received
one drop of moxifloxacin every 2 hours (Q2H), and the
second 10 patients received one drop of moxifloxacin
every 6 hours (Q6H). On the day of surgery, the patients
continued dosing as they had on the 3 preceding days.
Additionally, topical 0.5% moxifloxacin was administered
to all eyes 5 to 10 minutes preoperatively as a single drop.
Patients were asked to return their bottle of moxifloxacin
on the day of surgery to determine compliance to their
assigned dosing regimen. 
The last 10 patients enrolled received a 24-hour
dissolvable cross-linked corneal collagen shield (Oasis
Medical, Glendora, California) presoaked in moxifloxacin
FIGURE 1
Chemical structure of moxifloxacin hydrochloride (C21H24FN3O4-HCl).
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0.5% for 10 minutes prior to insertion into the eye sched-
uled for surgery. After placement, the eye was patched
with a soft shield. The collagen shield was placed in the
eye for approximately 4 hours (4H) in the first five
patients and 24 hours (24H) in the second five patients
prior to surgery.
Aqueous and vitreous samples were obtained before
infusion of any intraocular irrigating solution in order to
obtain pure samples. In the operative suite, approximately
0.1 mL of aqueous fluid was aspirated through a paracen-
tesis site using a 30-gauge needle attached to a syringe.
Within 10 minutes, 0.2 to 0.3 mL of vitreous fluid was
obtained using a vitreous cutting device attached to a
syringe via a short length of tubing. Aqueous and vitreous
samples were immediately frozen at –83°C. These
samples were shipped with dry ice in appropriate packag-
ing material to the University of Houston College of
Pharmacy, Houston, Texas. Moxifloxacin concentrations
were determined in each of the samples using a previously
described high-performance liquid chromatography tech-
nique.14 Aqueous and vitreous moxifloxacin concentra-
tions were compared with already established in vitro
MIC90 data.4,5 Student’s t test was performed to determine
if any significant differences existed between various
subsets of patients.
RESULTS
Indications for operation in the 30 patients were as follows
(Tables 2 and 3): macular hole (10 patients), epiretinal
membrane (10), branch retinal vein occlusion (3), central
retinal vein occlusion (2), diabetic macular edema (2),
chronic cystoid macular edema (1), vitreomacular traction
syndrome (1), and intraocular lens exchange (1).
Mean moxifloxacin concentrations in the topical Q2H
group for aqueous (n = 9) and vitreous (n = 10) were 2.28
± 1.23 µg/mL and 0.11 ± 0.05 µg/mL, respectively. Mean
moxifloxacin concentrations in the topical Q6H group for
aqueous (n = 10) and vitreous (n = 9) were 0.88 ± 0.88
µg/mL and 0.06 ± 0.06 µg/mL, respectively. Although the
mean aqueous concentration of moxifloxacin was signifi-
cantly different between the Q2H and the Q6H groups,
this was not the case for the vitreous (P = .01 and P = .08,
respectively) (Table 2 and Figure 2).
Compliance to assigned topical dosing regimens was
determined by counting the number of drops remaining
in each patient’s moxifloxacin 0.5% bottle on the day of
surgery. To determine the number of drops administered,
TABLE 1. IN VITRO SUSCEPTIBILITIES OF TOPICALLY ADMINISTERED MOXIFLOXACIN, LEVOFLOXACIN, OLFLOXACIN, AND CIPROFLOXACIN
MIC90 VALUES (µg/mL)*
MOXIFLOXACIN 0.5% LEVOFLOXACIN OFLOXACIN CIPROFLOXACIN
Q2H / Q6H 0.5%8 † 0.3%9 † 0.3%10 †
Mean aqueous penetration 2.28 ± 1.23 / 0.88 ± 0.88 1.00 ± 0.48 1.44 ± 0.24 0.44 ± 0.07
Mean vitreous penetration 0.11 ± 0.05 / 0.06 ± 0.06 – 0.37 ± 0.05 0.22 ± 0.04
Gram-positive organisms
Staphylococcus epidermidis 0.13 0.50 0.50 1.00
Staphylococcus aureus (MSSA) 0.06 0.25 0.50 0.50
Streptococcus pneumoniae 0.25 2.00 2.00 2.00
Streptococcus pyogenes 0.25 1.00 2.00 1.00
Bacillus cereus 0.13‡ – 0.50 –
Enterococcus faecalis 1.00 2.00 4.00 4.00
Gram-negative organisms
Proteus mirabilis 0.25 0.25 0.125 0.06
Pseudomonas aeruginosa 32.0 32.0 4.00 8.00
Haemophilus influenzae 0.06 0.06 4.00 0.016     
Escherichia coli 0.008 0.03 0.125 0.016
Klebsiella pneumoniae 0.13 0.13 0.50 0.06     
Neisseria gonorrhoeae 0.016 0.016 – 0.008
Anaerobic organisms
Bacteroides fragilis 2.00 2.00 – 8.00
Propionibacterium acnes 0.25‡ – – –
MIH90, minimum inhibitory concentration at which 90% of isolates are inhibited; MSSA, methicillin-sensitive S aureus.
*MIC90 data are from Bauernfeind4 and Osato et al.5
†Dash indicates data not available.
‡On file, Alcon Laboratories, Inc. 
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this number was subtracted from 78, because this is the
number of drops in an average 3-mL moxifloxacin 0.5%
bottle (on file, Alcon Laboratories, Inc). Only one patient
(No. 17, Table 2) did not return a bottle. The mean
number of moxifloxacin drops administered in the Q2H
and the Q6H groups was 42.90 ± 9.86 and 21.67 ± 4.72
drops, respectively.
Aqueous topical data from patient 1 and vitreous topi-
cal data from patient 20 were removed from the study
because either there was insufficient sample volume to
perform high-performance liquid chromatography
(HPLC) or concentrations were too low to be detected by
HPLC. In both the Q2H and the Q6H groups, there
appeared to be several values that were considered
outliers. For example, patient 2 had aqueous levels
approximately 13 times below the mean of the rest of the
Q2H group. We chose to include all data obtained in the
study, because the investigators could not explain these
high or low concentrations and attributed them to vari-
ability of moxifloxacin pharmacokinetics in individual
patients (Table 2).
Four of the 10 patients in the Q2H group and five of
the 10 patients in the Q6H group were phakic. In the Q2H
group, aqueous and vitreous moxifloxacin concentrations
were not significantly different when comparing phakic
versus pseudophakic eyes (P = .25 and P = .10, respec-
tively). The same was found in the Q6H group, where
aqueous and vitreous moxifloxacin concentrations were
not significantly different when comparing phakic versus
pseudophakic eyes (P = .08 and P = .12, respectively).
Collagen shields were placed for 3.75 ± 1.41 hours
prior to surgery in the 4H group and 24.80 ± 0.84 hours in
the 24H group. Mean moxifloxacin aqueous concentra-
tions in the 4H group (n = 5) were 0.30 ± 0.17 µg/mL.
Two of five patients in the 4H group had detectable vitre-
ous moxifloxacin levels of 0.03 µg/mL. In the 24H colla-
gen shield group, two of five patients had detectable aque-
TABLE 2.  PATIENT CHARACTERISTICS AND INTRAOCULAR MOXIFLOXACIN CONCENTRATIONS AFTER TOPICAL ADMINISTRATION
INDICATION PHAKIC DOSING NO. OF DROPS AQUEOUS VITREOUS
PATIENT NO. AGE (YR) FOR SURGERY STATUS REGIMEN ADMINISTERED µg/mL µg/mL
1 67 MH Phakic Q2H 39 –* 0.07
2 58 CME Pseudo Q2H 49 0.173 0.10
3 69 MH Phakic Q2H 47 2.393 0.07
4 70 ERM Phakic Q2H 47 4.244 0.10
5 55 MH Phakic Q2H 38 2.316 0.07
6 68 ERM Pseudo Q2H 25 3.182 0.18
7 69 MH Pseudo Q2H 44 1.713 0.08
8 84 MH Pseudo Q2H 63 3.488 0.13
9 66 CRVO Pseudo Q2H 38 1.394 0.09
10 77 BRVO Pseudo Q2H 39 1.655 0.22
11 76 ERM Pseudo Q6H 17 0.301 0.08
12 55 IOL Exchange Pseudo Q6H 27 0.122 0.20
13 72 MH Pseudo Q6H 26 0.955 0.08
14 61 BRVO Phakic Q6H 21 2.198 0.03
15 66 ERM Phakic Q6H 27 0.769 0.02
16 86 ERM Pseudo Q6H 13 0.294 0.06
17 69 ERM Pseudo Q6H –† 0.296 0.03
18 61 MH Phakic Q6H 20 0.816 0.03
19 70 ERM Phakic Q6H 21 2.709 0.04
20 59 MH Phakic Q6H 23 0.35 –*
BRVO, branch retinal vein occlusion; CME, chronic cystoid macular edema; CRVO, central retinal vein occlusion; ERM, epiretinal membrane; IOL,
intraocular lens; MH, macular hole.
*Not detected by high-performance liquid chromatography, presumably due to low concentration or insufficient sample volume.
†Moxifloxacin 0.5% bottle not returned.
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FIGURE 2
Mean intraocular moxifloxacin concentrations achieved after topical
administration.
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ous moxifloxacin levels of 0.04 ± 0.01 µg/mL. Vitreous
levels of moxifloxacin were undetectable in all five
patients in the 24H group (HPLC assay for moxifloxacin
can detect levels >0.025 µg/mL) (Table 3).
No serious adverse reactions were attributed to the
antibiotic agent or the collagen shield. In our series, only
one patient from the Q2H topical group complained of
mild ocular discomfort. No patients in our series
complained of nonocular adverse events. Corneal clarity
in all patients included in this study was described as
excellent by the contributing surgeons. 
DISCUSSION
After cataract extraction, bacterial endophthalmitis is
most commonly caused by S epidermidis (70% of isolates
in the Endophthalmitis Vitrectomy Study).1 This typically
presents as a moderately severe infection 5 to 7 days after
surgery. Less commonly, two other forms of endoph-
thalmitis can take place after cataract extraction. The first
is a chronic, indolent endophthalmitis that presents
several months after surgery and is usually caused by P
acnes.15 A second, less common form of postoperative
endophthalmitis is an early, fulminant type usually
presenting 2 to 4 days after surgery, which is caused by
Streptococcus or Staphylococcus species as well as gram-
negative organisms (most commonly P mirabilis1). One
reason we chose to study the intraocular penetration of
moxifloxacin is that the MIC90 values of moxifloxacin
against the pathogens most commonly responsible for
postoperative, post-traumatic, and bleb-associated
endophthalmitis were generally lower than those of the
other fluoroquinolone antibiotics we surveyed (Table 1).
In our study, MIC90 levels were far exceeded in the aque-
ous for a wide spectrum of pathogens in both the topical
Q2H and Q6H groups, including S epidermidis, S aureus,
S pneumoniae, S pyogenes, P acnes, H influenzae, E coli,
B cereus, N gonorrhoeae, P mirabilis, and other organ-
isms. Concentration of moxifloxacin in the vitreous after
topical administration did not exceed the MIC90 for
several organisms; however, in the Q2H group, the MIC
at which 50% of isolates are inhibited (MIC50) was
exceeded for S epidermidis, S aureus, S pneumoniae, H
influenzae, B cereus, and other gram-negative organisms.6
Topically administered moxifloxacin was unable to achieve
intraocular levels effective against Pseudomonas; further-
more, the MIC90 for Enterococcus was only exceeded in
the Q2H aqueous group. Although Pseudomonas and
Enterococcus are only very rarely encountered in postop-
erative endophthalmitis,1 moxifloxacin 0.5% may not be a
suitable treatment choice for intraocular infections known
to be caused by these organisms. 
Another reason we chose to study the intraocular
penetration of topically administered moxifloxacin 0.5% is
that older-generation fluoroquinolones, such as levofloxacin
0.5%, ofloxacin 0.3%, and ciprofloxacin 0.3%, have been
shown to achieve effective levels in the aqueous, but not the
vitreous, after topical administration in the noninflamed
human eye.8-10 Table 1 compares the mean intraocular
concentrations achieved with several other fluoro-
quinolones agents, as well as their corresponding MIC90
values, against the pathogens most commonly responsible
for bacterial endophthalmitis. The intent of this table is not
to directly compare the intraocular penetration of the
different agents, since the dosing frequency of each inves-
tigated fluoroquinolone was different. Additionally, given
the study design of these types of investigations, it is diffi-
cult to precisely determine if samples are being obtained
during drug peak or trough levels. Given these limitations
of Table 1, several important findings are apparent. First,
TABLE 3. PATIENT CHARACTERISTICS AND INTRAOCULAR MOXIFLOXACIN CONCENTRATIONS AFTER COLLAGEN SHIELD PLACEMENT
INDICATION PHAKIC AQUEOUS VITREOUS
PATIENT NO. AGE (YR) FOR SURGERY STATUS GROUP µg/mL µg/mL
1 75 DME Pseudo 4H 0.077 –
2 70 MH Phakic 4H 0.22 –
3 76 ERM Phakic 4H 0.328 0.03
4 75 ERM Phakic 4H 0.555 –
5 59 CRVO Phakic 4H 0.33 0.03
6 76 BRVO Pseudo 24H – –
7 68 MH Phakic 24H 0.046 –
8 62 DME Pseudo 24H – –
9 66 ERM Phakic 24H – –
10 60 VMTx Pseudo 24H 0.025 –
BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; DME, diabetic macular edema; 
ERM, epiretinal membrane; MH, macular hole; VMTx, vitreomacular traction syndrome.
*Dash indicates not detected by high-performance liquid chromatography, presumably due to low concentration or insufficient sample volume.
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no topically administered fluoroquinolone investigated
achieves intravitreal levels sufficient to exceed the MIC90
for the organisms that most commonly cause bacterial
endophthalmitis. Intravitreal concentration of moxifloxacin
0.5% Q2H comes very close to the MIC90 for S epidermidis
(the most common causative organism in bacterial endoph-
thalmitis). This concentration may be sufficient for prophy-
laxis, but is not sufficient for treatment of active infection.
Previous studies suggest that intraocular penetration of
systemic antibiotics may be higher in an eye that has
sustained trauma, is infected, or is inflamed (ie, the postop-
erative eye).16,17 This may be due to disruption of the blood-
ocular barrier, and it is conceivable that the intravitreal
penetration of topically administered moxifloxacin may be
high enough to exceed the MIC90 level for S epidermidis
and several other organisms of concern in the postoperative
setting. Another finding that becomes apparent upon
reviewing Table 1 is that compared to older-generation
fluoroquinolones, moxifloxacin concentration achieved in
the aqueous has fewer gaps in coverage for the organisms
most commonly implicated in bacterial endophthalmitis.
Previous studies have demonstrated that orally admin-
istered fourth-generation fluoroquinolones can achieve
therapeutic levels in the noninflamed human eye. Garcia-
Saenz and associates18 investigated the penetration of orally
administered moxifloxacin into the human aqueous humor
for potential use as a prophylactic agent in cataract surgery.
They found that moxifloxacin achieved a mean aqueous
concentration of 2.33 ± 0.85 µg/mL. Unfortunately, pene-
tration of moxifloxacin into the vitreous was not investi-
gated in this study. Gatifloxacin, another fourth-generation
fluoroquinolone, has been shown to achieve levels as high
as 1.34 ± 0.34 µg/mL and 1.08 ± 0.54 µg/mL in the human
vitreous and aqueous after oral administration, respec-
tively.19 Although oral administration of a fourth-generation
fluoroquinolone results in intravitreal concentrations
several times higher than after topical administration, an
interesting finding is that topically administered Q2H
moxifloxacin 0.5% can achieve aqueous levels comparable
to those after oral administration. Therefore, topically
administered moxifloxacin 0.5% may be useful in the
management of infections limited to the anterior segment.
One example of such an infection is localized conjunctival
filtering bleb infection, or “blebitis.” The most common
causative organisms in delayed-onset bleb-associated
endophthalmitis are Streptococcus and Staphylococcus
species.20  H influenzae is also commonly encountered in
this condition. The concentration of moxifloxacin achieved
after topical administration in the aqueous is several times
higher than the MIC90 for these organisms. If blebitis
progresses to bleb-associated endophthalmitis, one may
consider the addition of an orally administered fourth-
generation fluoroquinolone as an adjunct to the current
management of bleb-associated endophthalmitis.
The collagen shield data obtained from this study reveal
that peak aqueous levels of moxifloxacin occur soon after
surgery. This is when a high level of antibiotic is most needed
to clear the anterior chamber of bacteria remaining in the
eye. In the 4H collagen shield group, the MIC90 and MIC50
for several organisms that most commonly cause postopera-
tive endophthalmitis were exceeded.4-6 By 24 hours, negligi-
ble levels of moxifloxacin were found in the eye. This is
consistent with other studies investigating drug delivery from
collagen shields, which show that peak intraocular drug levels
occur in the first 4 hours of collagen shield application.21
Therapeutic moxifloxacin levels in the vitreous cannot be
achieved with this method of drug delivery, and the clinical
significance of this is yet to be determined.
There are several advantages to using collagen shields
for moxifloxacin delivery in the immediate postoperative
period. One such advantage is the ability to leave the eye
patch undisturbed after surgery while the collagen shield
releases antibiotic. Additionally, there is evidence that
collagen shields have a beneficial effect on the corneal
epithelium and promote healing.13 Collagen shields have
advantages over subconjunctival injections as well; these
include avoiding inadvertent globe perforation and
subconjunctival hemorrhage. Additionally, pain associated
with subconjunctival antibiotic injection can be avoided
with the use of a collagen shield when cataract surgery is
performed using topical anesthesia. Lastly, with the
advent of sutureless 25-gauge vitrectomy surgery, the
vitreoretinal specialist should consider the theoretical risk
of serious retinal toxicity if a subconjunctivally adminis-
tered antibiotic such as gentamicin were to enter an air-
filled eye through an unsutured sclerotomy site. 
Moxifloxacin 0.5% is unique in that it is free of
preservatives, specifically benzalkonium chloride. The
lack of this preservative is valuable when using a collagen
shield delivery device, because there is a theoretical risk
of preservatives causing corneal damage after sustained
drug delivery. Corneal clarity was rated as excellent by the
contributing surgeons for all 30 patients participating in
this study; however, no formal fluorescein staining was
performed to evaluate subtle corneal epithelial changes. 
Moxifloxacin 0.5% is very well tolerated; the majority
of adverse reactions are described as mild. These most
commonly include dry eye, ocular hyperemia, ocular
discomfort, and ocular itching. In our series, only one
patient from the Q2H topical group complained of mild
ocular discomfort. No patients in our series complained of
nonocular adverse events. The dosage of moxifloxacin
0.5% recommended by Alcon Laboratories, Inc, is one
drop three times a day (bacterial conjunctivitis indica-
tion). In our study design, we chose to use a regimen of
Q2H and Q6H. Our rationale for dosing at Q2H was to
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determine if intensive topical therapy could be used to
obtain therapeutic levels in the vitreous. The Q6H dosing
schedule was included in the study because this is a
commonly used dosing regimen for cataract surgery
prophylaxis. After calculation of the number of drops that
were self-administered, patient compliance in both
groups was considered excellent (Table 2). 
The authors would like to emphasize that the purpose
of this research is to provide proof-of-principle that moxi-
floxacin 0.5% can attain therapeutic intraocular concen-
trations. Moxifloxacin 0.5% may be beneficial for prophy-
laxis against the risk of infection after eye surgery or
intravitreal injections; however, it should be noted that
antibiotics are only one component of a thorough prophy-
lactic regimen. 
In summary, moxifloxacin has a spectrum of coverage
that appropriately encompasses the most common
causative organisms in endophthalmitis. The pharmacoki-
netic findings of this investigation reveal that topically
administered moxifloxacin 0.5% can achieve relatively
high aqueous concentrations. Although aqueous moxi-
floxacin levels achieved through the use of a collagen
shield delivery device are lower, it is conceivable that
intraocular levels of moxifloxacin may be higher in an eye
that has undergone surgery. Additionally, there are several
advantages to the collagen shield route of delivery that
make it appealing in the immediate postoperative period.
Future studies will be needed to precisely define the role
of fourth-generation fluoroquinolones and presoaked
collagen shields in the prophylaxis or management of
intraocular infections.
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DISCUSSION
DR M. GILBERT GRAND. Endophthalmitis is among the
most feared complications of intraocular surgery.  While
the incidence is low, because of the potential for cata-
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strophic loss of vision, a variety of prophylactic methods
have been embraced in hopes of preventing such infec-
tions.  These include the use of antiseptic solutions to
cleanse the operative field, proper sterilization of instru-
ments, fluids, sutures and implants, and the prophylactic
use of antibiotics.  There is ample evidence that the use of
preoperative povidone-iodine and antibiotics is associated
with the reduction of viable microorganisms in the ocular
flora, a reduction in the incidence of positive aqueous
cultures at the completion of surgery, and a decreased
incidence of endophthalmitis.1 Considerable debate
remains regarding the ideal prophylactic regimen; specif-
ically, which antibiotic to use, the frequency and duration
of treatment, route of administration, and the timing of
administration of the drug in relation to surgery.  There is
also debate regarding potential deleterious effects of
prophylactic use of antibiotics, including the potential
acceleration of development of resistance, ocular toxicity,
and alterations of the normal ocular flora to allow the
growth of more virulent organisms.  
The authors have presented data showing the
bioavailability of topically applied moxifloxacin in the
aqueous of non-inflamed eyes.  Their data indicate
concentrations of moxifloxacin in the aqueous that exceed
the MIC90 of organisms that most commonly cause acute
postoperative bacterial endophthalmitis, blebitis, and
filter bleb-associated endophthalmitis.  
In reviewing this manuscript, it is apparent that the
study population was, in fact, small and was further
divided into multiple smaller treatment groups.  The data
points collected show a wide range of values, sometimes
as wide as the mean value itself.  Furthermore, compli-
ance, as measured by drop count, appeared to be incon-
sistent.  Yet despite these concerns, the study strongly
suggests that topically applied moxifloxacin potentially
may be of great value as a prophylactic antibiotic to
reduce the risk of acute postoperative bacterial endoph-
thalmitis.  The authors, however, prudently remind us that
the use of antibiotics, whether preoperatively, intraopera-
tively or postoperatively, is only one aspect in an overall
scheme to prevent endophthalmitis.  Perhaps the most
significant finding of the study is the potential value of
topical moxifloxacin in the treatment of H. influenzae or
Streptococcus-induced blebitis and as an adjunct to intrav-
itreal or systemic therapy in the treatment of filter bleb-
associated endophthalmitis.
The data presented stimulate a number of questions:
what is the ideal timing and frequency of administration
of moxifloxacin preoperatively to achieve a significant
reduction in viable microorganisms in the ocular flora?
Will topical moxifloxacin administered for two hours prior
to surgery achieve the same reduction in ocular flora and
the same concentration in the aqueous as treatment
administered over three days preoperatively? Can modifi-
cations in the design and construction of the matrix of
collagen shields be achieved that would allow a more
prolonged administration of moxifloxacin or similar drugs
to achieve adequate antibiotic concentrations in the aque-
ous and vitreous postoperatively without associated ocular
toxicity?  Finally, despite the potential broad spectrum
coverage and bioavailability of moxifloxacin, in the hopes
of preventing the induction of resistance, would it be
prudent to avoid the use of fourth generation fluoro-
quinolones as prophylactic agents and reserve them only
for treatment of infections such as blebitis or filter bleb
endophthalmitis?
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DR SEENU M. HARIPRASAD. Dr Grand’s first question is
astute.  He asks if there is a difference in the ocular flora
if moxifloxacin is dosed for three days versus for only two
hours preoperatively?  A very similar question was
answered by Dr Ta and colleagues two years ago at
Stanford; they dosed ofloxacin for three days in one group
of patients and dosed ofloxacin in a second group one
hour preoperatively.  They found that positive conjuncti-
val cultures were found prior to surgery in about 20
percent of eyes which received three days of ofloxacin
versus 40 percent of eyes that received ofloxacin only right
before surgery.  Similarly, postoperatively, those eyes
which had received ofloxacin for three days had less than
50 percent ocular surface contamination compared to the
group that received ofloxacin only right before surgery (it
should be noted that all patients received a povidone-
iodine scrub).  Therefore, this data strongly suggests that
a longer preoperative antibiotic dosing regimen is more
effective in eliminating bacteria from the ocular surface.
To address Dr Grand’s second question, the effective-
ness of a corneal collagen shield as a drug delivery device
depends on its drug uptake and its subsequent rate of
release.  The factors that determine this include collagen
shield cross-linking versus non-cross linking, dissolution
time of the collagen shield, and water-solubility of the
drug.  A cross-linked shield (such as the one we used in
this study) can provide more desirable drug delivery than
non-cross linked shields because drug levels can be
sustained for longer periods of time.  Likewise, longer
dissolution times are also preferable, and that is why we
used a 24-hour collagen shield rather than a 12-hour
shield.  So to answer your question, Dr Grand, the design
of a “better” collagen shield may be achieved by altering
the molecular structure of the shield and possibly the
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physicochemical properties of the drug. 
Finally, the proper use of ophthalmic topical fluoro-
quinolones represents an insignificant selection pressure
for promoting resistant bacteria.  I use the term “proper”
to mean the use of a topical antibiotic at therapeutic levels
for a short period of time.  Approximately 200,000 kilo-
grams of fluoroquinolones are used annually of which only
24 kilograms constitute ocular use.  Therefore, my
impression is that agriculture, veterinary, general medi-
cine, and surgical uses of fluoroquinolones have a much
greater selection pressure for the development of resist-
ant organisms compared to ophthalmology.  
I would like to convey my gratitude to the program
committee for allowing me to present our research today
and once again I would like to thank Dr Grand for his
meticulous review of our paper.

